Hightide Therapeutics Inc (HK:2511) has released an update.
HighTide Therapeutics Inc., a biopharmaceutical company focusing on metabolic and digestive disease therapies, has announced its unaudited interim results for the first half of 2024. The company boasts a robust in-house developed pipeline with five drug candidates, including HTD1801, which is undergoing multiple clinical trials. HighTide is poised to meet unmet clinical needs with its innovative and multifunctional treatments, having operations in the US, China, Hong Kong, and Australia.
For further insights into HK:2511 stock, check out TipRanks’ Stock Analysis page.